Sandoz Group AG Sponsored ADR (SDZNY)
(Delayed Data from OTC)
$56.03 USD
-0.75 (-1.31%)
Updated Aug 6, 2025 11:16 AM ET
3-Hold of 5 3
B Value A Growth C Momentum A VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
SDZNY 56.03 -0.75(-1.31%)
Will SDZNY be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for SDZNY based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SDZNY
Zacks Industry Outlook Highlights Sandoz, Teva Pharmaceuticals and Viatris
3 Generic Drug Stocks to Watch Amid Pricing Pressure & Tariff Threats
SDZNY: What are Zacks experts saying now?
Zacks Private Portfolio Services
SDZNY vs. STVN: Which Stock Should Value Investors Buy Now?
Zacks Industry Outlook Dr. Reddy's, Sandoz and Teva Pharmaceuticals
3 Generic Drug Stocks to Watch Amid Trade War Jitters & Inflation Woes
Other News for SDZNY
Bayer Stock Is Soaring Ahead Of Its Earnings Release
Sandoz signs non-binding term sheet with Evotec SE to acquire its Just-Evotec Biologics ...
Sandoz to acquire Just-Evotec Biologics from Evotec for $300M
Novartis fails in bid to block MSN Pharma’s generic Entresto as court denies injunction
Sandoz issues recall for additional lot of Cefazolin for injection